EGRX
Eagle Pharmaceuticals, Inc.
EGRX
EGRX
Delisted
EGRX was delisted on the 2nd of October, 2024.
160 hedge funds and large institutions have $555M invested in Eagle Pharmaceuticals, Inc. in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 55 increasing their positions, 66 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
95% less call options, than puts
Call options by funds: $24K | Put options by funds: $485K
Holders
160
Holding in Top 10
1
Calls
$24K
Puts
$485K
Top Buyers
| 1 | +$11.1M | |
| 2 | +$8.2M | |
| 3 | +$3.49M | |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.76M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.67M |
Top Sellers
| 1 | -$9.03M | |
| 2 | -$8.82M | |
| 3 | -$6.2M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$4.36M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$3.85M |